BioSpace News Archive

Certara, Inc., a global leader in biosimulation, announced the pricing of its underwritten public offering of 10 million shares of its common stock by certain existing stockholders at a price to the public of $31.00 per share.

Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), today announced that it will host a conference call for investors and shareholders to discuss the positive topline results from its recently completed Phase 2b CONTROL Study of Congenital Ichthyosis for its lead asset, TMB-001.

A novel gene therapy for hemophilia A led to sustained expression of the clotting factor those patients lack, resulting in a reduction – or in some cases complete elimination – of painful and potentially life-threatening bleeding events, according to a new study led by researchers at Children’s Hospital of Philadelphia (CHOP).

Gannex Pharma Co., Ltd., today announces dosing of the first subject in the U.S. Phase I trial for ASC43F, a first-in-class, fixed-dose combination (FDC) oral tablet with dual targets of thyroid hormone receptor beta (THRβ) and farnesoid X receptor (FXR) for the treatment of non-alcoholic steatohepatitis (NASH).

Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced a strategic partnership with Merck KGaA, Darmstadt, Germany, in companion diagnostics (CDx) development for the MET inhibitor tepotinib in the mainland China market.

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the appointment of Tracey L. McCain, Esq. to its Board of Directors.

NANOBIOTIX, a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced that Laurent Levy, co-founder and chief executive officer, will participate in a virtual fireside chat at the 4th annual Evercore ISI HealthCONx Conference on Thursday, December 2, 2021, at 1:00 PM EST / 7:00 PM CET.

Algernon Pharmaceuticals Inc., a clinical stage pharmaceutical development company, announces that it intends to consolidate its Class A common shares on a one-hundred to one basis.

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need, announced that it has commenced an underwritten public offering of its common stock and pre-funded warrants.